{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:07:41Z","timestamp":1791497261442,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bpobgyn.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:09:39Z","timestamp":1593050979000},"page":"13-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["The pharmacodynamics and safety of progesterone"],"prefix":"10.1016","volume":"69","author":[{"given":"Paul C.M.","family":"Piette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.maturitas.2004.01.001","article-title":"Pharmacological profile of progestins","volume":"47","author":"Sitruk-Ware","year":"2004","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/humupd\/dmi046","article-title":"New progestagens for contraceptive use","volume":"12","author":"Sitruk-Ware","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0026-895X(24)23238-7","article-title":"Allopregnanolone synthesis in cerebellar granule cells: roles in regulation of GABAA receptor expression and function during progesterone treatment and withdrawal","volume":"57","author":"Follesa","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00003081-199538040-00024","article-title":"Micronised progesterone: vaginal and oral uses","volume":"38","author":"Simon","year":"1995","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0378-5122(94)00882-8","article-title":"Influence of route of administration on progesterone metabolism","volume":"21","author":"de Ligni\u00e8res","year":"1995","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13697137.2018.1472567","article-title":"Progesterone for treatment of symptomatic menopausal women","volume":"21","author":"Prior","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib8","first-page":"845180","article-title":"Progesterone and bone: actions promoting bone health in women","volume":"2010","author":"Seifert-Klauss","year":"2010","journal-title":"J\u00a0Osteoporos"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/13697137.2018.1467400","article-title":"Progesterone for the prevention and treatment of osteoporosis in women","volume":"21","author":"Prior","year":"2018","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0015-0282(16)56935-0","article-title":"Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study","volume":"62","author":"Miles","year":"1994","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/humupd\/5.4.365","article-title":"Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus","volume":"5","author":"Cicinelli","year":"1999","journal-title":"Hum Reprod Update"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/humupd\/6.2.139","article-title":"Comparison between different routes of progesterone administration as luteal phase support in infertility treatments","volume":"6","author":"Tavaniotou","year":"2000","journal-title":"Hum Reprod Update"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.rbmo.2013.10.022","article-title":"Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey","volume":"28","author":"Vaisbuch","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1210\/en.2012-1138","article-title":"Progesterone receptors: a key for neuroprotection in experimental stroke","volume":"153","author":"Liu","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1073\/pnas.1001422107","article-title":"Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer\u2019s disease","volume":"107","author":"Wang","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pneurobio.2013.08.005","article-title":"Allopregnanolone in the brain: protecting pregnancy and birth outcomes","volume":"113","author":"Brunton","year":"2014","journal-title":"Prog Neurobiol"},{"issue":"10050","key":"10.1016\/j.bpobgyn.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0140-6736(16)31016-9","article-title":"Vaginal progesterone prophylaxis for preterm birth [the OPPTIMUM study]: a multicentre, randomised, double-blind trial","volume":"388","author":"Norman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00042192-200101000-00004","article-title":"Sleep in menopause: differential effects of two forms of hormone replacement therapy","volume":"8","author":"Montplaisir","year":"2001","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib20","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1210\/jc.2010-2558","article-title":"Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women","volume":"96","author":"Caufriez","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.psyneuen.2018.04.001","article-title":"Sleep after intranasal progesterone vs. zolpidem and placebo in postmenopausal women - a randomized, double-blind cross over study","volume":"92","author":"Sch\u00fcssler","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pneurobio.2013.09.004","article-title":"Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors","volume":"113","author":"Schumacher","year":"2014","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/13697137.2018.1462792","article-title":"The history of natural progesterone, the never-ending story","volume":"21","author":"Piette","year":"2018","journal-title":"Climacteric"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10571-018-0627-0","article-title":"Steroids in stroke with special reference to progesterone","volume":"39","author":"Guennoun","year":"2019","journal-title":"Cell Mol Neurobiol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13697137.2019.1622085","article-title":"Impact of endogenous and exogenous progesterone exposure on stress biomarkers: a systematic review","volume":"22","author":"Stadler","year":"2019","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.12891\/ceog3820.2018","article-title":"Depression, anxiety, and stress after preterm delivery: role of previous progesterone therapy","volume":"XLV","author":"Djakocic","year":"2018","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.bpobgyn.2020.06.002_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib28","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46S1","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib29","series-title":"Progesteron and progestins","first-page":"179","article-title":"Effect of progesterone and progestins on water and salt metabolism","author":"Corvol","year":"1983"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib30","first-page":"560","article-title":"Interaction of synthetic progestagens with renal mineralocorticoid receptors","volume":"92","author":"Wambach","year":"1979","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.290.6461.13","article-title":"Natural progesterone and antihypertensive action","volume":"290","author":"Rylance","year":"1985","journal-title":"Br Med J"},{"issue":"9\u201310","key":"10.1016\/j.bpobgyn.2020.06.002_bib32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.steroids.2007.12.004","article-title":"Honey, we need to talk about the membrane progestin receptors","volume":"73","author":"Fernandes","year":"2008","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib33","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1071\/RD13430","article-title":"Changes in myometrial expression of progesterone receptor membrane components 1 and 2 are associated with human parturition at term","volume":"28","author":"Wang","year":"2016","journal-title":"Reprod Fertil Dev"},{"issue":"15","key":"10.1016\/j.bpobgyn.2020.06.002_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.mce.2016.06.027","article-title":"Membrane P4 receptors in reproduction and cancer","volume":"434","author":"Valadez-Cosmes","year":"2016","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib35","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1210\/jc.2004-2130","article-title":"Prevention of endometrial apoptosis: randomized prospective comparison of human chorionic gonadotropin versus progesterone treatment in the luteal phase","volume":"90","author":"Lovely","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.fertnstert.2016.11.029","article-title":"Luteal start vaginal micronised progesterone improves pregnancy success in women with recurrent pregnancy loss","volume":"107","author":"Stephenson","year":"2017","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/bdrb.20089","article-title":"\u201cNatural\u201d progesterone: information on fetal effects","volume":"77","author":"Golub","year":"2006","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib38","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJMra000763","article-title":"Implantation and the survival of early pregnancy","volume":"345","author":"Norwitz","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.06.002_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/molehr\/gam078","article-title":"The effects of progesterone on apoptosis in the human trophoblast-derived HTR-8\/SV neo cells","volume":"13","author":"Liu","year":"2007","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jri.2009.06.262","article-title":"Progesterone in pregnancy; receptor\u2013ligand interaction and signaling pathways","volume":"83","author":"Szekeres-Bartho","year":"2009","journal-title":"J\u00a0Reprod Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.bpobgyn.2020.06.002_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/humrep\/15.suppl_1.46","article-title":"Progesterone inhibits in-vitro embryotoxic Thl cytokine production to trophoblast in women with recurrent pregnancy loss","volume":"15","author":"Choi","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jsbmb.2005.08.010","article-title":"Progesterone and the immunology of pregnancy","volume":"97","author":"Druckmann","year":"2005","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000087953","article-title":"Progesterone-dependent immunomodulation","volume":"89","author":"Szekeres-Bartho","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib44","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.2042-7158.2012.01464.x","article-title":"Novel actions of progesterone: what we know today and what will be the scenario in the future?","volume":"64","author":"Kaorea","year":"2012","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.fertnstert.2006.07.1506","article-title":"Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronised progesterone or oral dydrogesterone","volume":"87","author":"Czajkowski","year":"2007","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2009.05.012","article-title":"Progesterone suppresses the fetal inflammatory response ex\u00a0vivo","volume":"201","author":"Schwartz","year":"2009","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.bpobgyn.2020.06.002_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/humrep\/15.suppl_1.90","article-title":"Hormonal influence on the uterine contractility during ovarian stimulation","volume":"15","author":"Fanchin","year":"2000","journal-title":"Hum Reprod"},{"issue":"26","key":"10.1016\/j.bpobgyn.2020.06.002_bib48","first-page":"2933","article-title":"Influence of 5alpha- and 5beta-reduced progestins on the contractility of isolated human myometrium at term","volume":"68","author":"Perusqu\u00eda","year":"2001","journal-title":"J\u00a0Life Sci"},{"issue":"9607","key":"10.1016\/j.bpobgyn.2020.06.002_bib49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(08)60108-7","article-title":"Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth","volume":"371","author":"Iams","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bpobgyn.2020.06.002_bib50","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1194\/jlr.P093427","article-title":"Metabolism of cholesterol and progesterone is differentially regulated in primary trophoblastic subtypes and might be disturbed in recurrent miscarriages","volume":"60","author":"Vondra","year":"2019","journal-title":"J\u00a0Lipid Res"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib51","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00006254-200205001-00001","article-title":"Tocolysis: an update for the practitioner","volume":"57","author":"Rodts-Palenik","year":"2002","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib52","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/09513590.2012.730576","article-title":"The role of P4 in maternal and fetal medicine","volume":"28","author":"Di Renzo","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib53","first-page":"CD005943","article-title":"Progestogen for treating threatened miscarriage","volume":"8","author":"Wahabi","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(06)69204-0","article-title":"Recurrent miscarriage","volume":"368","author":"Rai","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12884-018-2002-z","article-title":"Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 Weeks gestation: a prospective cohort study","volume":"18","author":"Ku","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"issue":"22","key":"10.1016\/j.bpobgyn.2020.06.002_bib56","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMoa1504927","article-title":"A\u00a0randomized trial of progesterone in women with recurrent miscarriages","volume":"373","author":"Coomarasamy","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib57","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa1813730","article-title":"A\u00a0randomized trial of progesterone in women with bleeding in early pregnancy","volume":"380","author":"Coomarasamy","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.12.006","article-title":"Micronised vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence","author":"Coomarasamy","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib59","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0015-0282(99)00495-1","article-title":"Embryonic karyotype of abortuses in relation to the number of previous miscarriages","volume":"73","author":"Ogasawara","year":"2000","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.06.002_bib60","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/1471-0528.16068","article-title":"The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial","volume":"127","author":"Okeke Ogwulu","year":"2020","journal-title":"Br J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib61","first-page":"216","article-title":"The neglected luteal phase after natural conception: rescue by early progesterone supplementation","volume":"2","author":"Tesarik","year":"2019","journal-title":"Cur Op Gyn Obs"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib62","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0002-9378(73)90517-6","article-title":"The effect s of luteectomy and P4 replacement therapy in early pregnant patients","volume":"115","author":"Csapo","year":"1973","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0015-0282(16)59890-2","article-title":"Pregnancies after replacement of frozen-thawed embryos in a donation program","volume":"49","author":"Salat-Baroux","year":"1988","journal-title":"Fertil Steril"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib64","first-page":"188","article-title":"Progesterone administration in patients with absent ovaries","volume":"34","author":"Devroey","year":"1989","journal-title":"Int J Fertil"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib65","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/oxfordjournals.humrep.a137138","article-title":"Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure","volume":"5","author":"Bourgain","year":"1990","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.fertnstert.2018.02.132","article-title":"Premature progesterone elevation in controlled ovarian stimulation: to make a long story short","volume":"109","author":"Adda-Herzog","year":"2018","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.bpobgyn.2020.06.002_bib67","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in\u00a0vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.fertnstert.2017.09.033","article-title":"Effect of the initiation of progesterone supplementation in in\u00a0vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial","volume":"109","author":"Gao","year":"2018","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.06.002_bib69","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/jcem.87.6.8609","article-title":"Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium","volume":"87","author":"Mesiano","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib70","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1067\/mob.2002.121108","article-title":"Connexin 43 expression in normal versus prolonged labor","volume":"186","author":"Pierce","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib71","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7827-4-24","article-title":"Prolonged labour associated with lower expression of syndecan 3 and connexin 43 in human uterine tissue","volume":"4","author":"Cluff","year":"2006","journal-title":"Reprod Biol Endocrinol"},{"issue":"2 Pt 1","key":"10.1016\/j.bpobgyn.2020.06.002_bib72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.AOG.0000275287.08520.4a","article-title":"Prediction and prevention of recurrent spontaneous preterm birth","volume":"110","author":"Spong","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib73","first-page":"401","article-title":"Pharmacological use of progesterone and 17-alpha hydroxyprogesterone caproate in the prevention of preterm delivery","volume":"61","author":"Facchinetti","year":"2009","journal-title":"Minerva Ginecol"},{"issue":"6019","key":"10.1016\/j.bpobgyn.2020.06.002_bib74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1126\/science.1197454","article-title":"The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2","volume":"331","author":"Li","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib75","first-page":"CD004947","article-title":"Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth","volume":"7","author":"Dodd","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/jpm-2012-0272","article-title":"A\u00a0blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix","volume":"41","author":"Romero","year":"2013","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib77","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2007-0077","article-title":"Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A","volume":"92","author":"Merlino","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.06.002_bib78","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1210\/me.2005-0243","article-title":"Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term","volume":"20","author":"Karteris","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib79","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00404-010-1365-9","article-title":"The onset of human parturition","volume":"281","author":"Kamel","year":"2010","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.06.002_bib80","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.4049\/jimmunol.1801350","article-title":"Effector and activated T cells induce preterm labor and birth that is prevented by treatment with progesterone","volume":"202","author":"Arenas-Hernandez","year":"2019","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.06.002_bib81","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/1471-0528.15801","article-title":"Vaginal progesterone is associated with decreased group B streptococcus colonisation at term: a retrospective cohort study","volume":"126","author":"Ma'ayeh","year":"2019","journal-title":"BJOG"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib82","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajog.2004.07.077","article-title":"Progesterone enhances the tocolytic effect of ritodrine in isolated pregnant human myometrium","volume":"192","author":"Chanrachakul","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib83","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ajog.2008.06.085","article-title":"Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions","volume":"199","author":"Ruddock","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0029-1234033","article-title":"Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study","volume":"27","author":"O'Brien","year":"2010","journal-title":"Am J Perinatol"},{"issue":"18","key":"10.1016\/j.bpobgyn.2020.06.002_bib85","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3109\/14767058.2014.892922","article-title":"The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial","volume":"27","author":"Briery","year":"2014","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.026","article-title":"Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial","volume":"206","author":"Rozenberg","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.06.002_bib87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0028-2243(91)90118-5","article-title":"The use of micronised progesterone in the treatment of menace of preterm delivery","volume":"40","author":"Noblot","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6482","key":"10.1016\/j.bpobgyn.2020.06.002_bib88","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/bmj.290.6482.1617","article-title":"Progesterone and the premenstrual syndrome: a double blind crossover trial","volume":"290","author":"Dennerstein","year":"1985","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2826.1995.tb00744.x","article-title":"Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors","volume":"7","author":"D1","year":"1995","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0029-7844(97)00417-1","article-title":"Progesterone metabolite allopregnanolone in women with premenstrual syndrome","volume":"90","author":"Rapkin","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib91","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/endrev\/bnz001","article-title":"Progesterone and breast cancer","volume":"41","author":"Trabert","year":"2020","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-011-1394-5","article-title":"Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells","volume":"131","author":"Courtin","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"Suppl 2","key":"10.1016\/j.bpobgyn.2020.06.002_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/09513590.2012.706670","article-title":"Percutaneous estradiol\/oral micronised progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens\/medroxyprogesterone acetate in the breasts of healthy women in\u00a0vivo","volume":"28","author":"Murkes","year":"2012","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib94","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.fertnstert.2010.09.062","article-title":"Effects of percutaneous estradiol\u2013oral progesterone versus oral conjugated equine estrogens\u2013medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women","volume":"95","author":"Murkes","year":"2011","journal-title":"Fertil Steril"},{"issue":"7560","key":"10.1016\/j.bpobgyn.2020.06.002_bib95","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib97","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2007.13.4338","article-title":"Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor\u2013defined invasive breast cancer","volume":"26","author":"Fournier","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib98","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0960-0760(98)00028-4","article-title":"Progestins and breast cancer","volume":"65","author":"Pasqualini","year":"1998","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"10\u201313","key":"10.1016\/j.bpobgyn.2020.06.002_bib99","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/13697137.2011.648232","article-title":"Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells","volume":"15","author":"Ruan","year":"2012","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib101","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr3422","article-title":"Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors","volume":"15","author":"Wiebe","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib102","first-page":"1","article-title":"PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo controlled xenograft study","author":"Cai","year":"2020","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/humupd\/dmy039","article-title":"The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review","volume":"25","author":"Oliver-Williams","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"3","key":"10.1016\/j.bpobgyn.2020.06.002_bib104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial","volume":"273","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bpobgyn.2020.06.002_bib105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/13697137.2018.1446931","article-title":"Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis","volume":"21","author":"Scarabin","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib106","doi-asserted-by":"crossref","first-page":"l601","DOI":"10.1136\/bmj.l601","article-title":"Postmenopausal hormone therapy and risk of venous thromboembolism: what about progesterone?","volume":"364","author":"Scarabin","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.bpobgyn.2020.06.002_bib107","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00246-015-1190-9","article-title":"The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy","volume":"36","author":"Zaqout","year":"2015","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib108","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0140-6736(17)32059-7","article-title":"Association between oral intake of dydrogesterone during early pregnancy and congenital heart disease: a case-control study","volume":"390","author":"Zaqout","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib109","article-title":"Cardiac birth defects induced by maternal medications","volume":"1","author":"Koren","year":"2020","journal-title":"Prenat Cardiol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2020.06.002_bib110","first-page":"2212","article-title":"Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial","volume":"33","author":"Griesinger","year":"2018","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib111","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/humrep\/dex023","article-title":"A\u00a0Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in\u00a0vitro fertilization","volume":"32","author":"Tournaye","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib112","series-title":"Guideline of the European society of human reproduction and embryology","year":"2019"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.06.002_bib113","doi-asserted-by":"crossref","first-page":"294","DOI":"10.11622\/smedj.2016080","article-title":"Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques","volume":"58","author":"Nadarajah","year":"2017","journal-title":"Singap Med J"},{"issue":"5","key":"10.1016\/j.bpobgyn.2020.06.002_bib114","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa067815","article-title":"Progesterone and the risk of preterm birth among women with a short cervix","volume":"357","author":"Fonseca","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2020.06.002_bib115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/uog.15948","article-title":"Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age","volume":"48","author":"Vedel","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2020.06.002_bib116","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40168-016-0223-9","article-title":"The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk","volume":"5","author":"Kindinger","year":"2017","journal-title":"Microbiome"},{"issue":"9","key":"10.1016\/j.bpobgyn.2020.06.002_bib117","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2337\/dc07-0564","article-title":"Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery","volume":"30","author":"Rebarber","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.bpobgyn.2020.06.002_bib118","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","volume":"216","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2020.06.002_bib119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0039-3400227","article-title":"17-OHPC to prevent recurrent preterm birth in singleton gestations [PROLONG study]: a multicenter, international, randomized double-blind trial","volume":"37","author":"Blackwell","year":"2020","journal-title":"Am J Perinatol"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693420300924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693420300924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:12:15Z","timestamp":1761498735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693420300924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":119,"alternative-id":["S1521693420300924"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.06.002","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacodynamics and safety of progesterone","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}